Cencora's quality profile sits below the minimum acceptable threshold — free cash flow is negative, margins have compressed sharply to -30.1%, and leverage is elevated — while a perfect four-quarter beat streak and 8.4% upside to the analyst target create a tension between business-quality concerns and near-term earnings execution.
Thesis pillars
- Value Trap Margin Compression Leverage→Stable
- Quality Below Minimum Threshold→Stable
- Negative Free Cash Flow Red Flag→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Nov 25, 2025· older than 90 days
Cencora, Inc. (COR) Stock Analysis
Range Bound setup
Healthcare · Medical Distribution
Sell if holding. Engine safety override at $337.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality.
Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals, pharmacies, physicians, and veterinarians across the U.S. and select global markets through two segments: U.S. Healthcare Solutions and International Healthcare... Read more
Sell if holding. Engine safety override at $337.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Score 5.1/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: moderate.
Recent developments
updated Oct 30, 2026Recent Developments — Cencora, Inc.
Latest news
- NEWS Morgan Stanley Maintains Cencora at Overweight and Raises Price Target — fiscal.ai Oct 30, 2026 positive
- NEWS Morgan Stanley Maintains Overweight on Cencora, Raises Price Target to $377 — benzinga Oct 30, 2026 positive
- NEWS Camino and Nittetsu Launch Next Phase of Detailed Engineering for the Puquios Copper Project — fiscal.ai Oct 27, 2026 neutral
- NEWS Baird Maintains Outperform on Cencora, Raises Price Target to $375 — benzinga Oct 22, 2026 positive
- NEWS Baird Adjusts Price Target on Cencora to $375 — fiscal.ai Oct 21, 2026 neutral
Latest item Oct 30, 2026 · Generated 2026-11-03T11:59:06Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomertop ten customers66%10-K Item 1A: 'Our top ten customers, including governmental agencies, represented approximately 66% of revenue in fiscal 2025'
- MEDIUMCustomerWalgreens and Boots25%10-K Item 1A: 'Walgreens and Boots together accounted for approximately 25% of our revenue in fiscal 2025'
- LOWCustomerEvernorth Health Services13%10-K Item 1A: 'Evernorth Health Services accounted for approximately 13% of our revenue in fiscal 2025'
Material Events(8-K, last 90d)
- 2026-03-17Item 5.02HIGHCFO James F. Cleary announced retirement as EVP and CFO effective June 30, 2026; no successor named at time of filing. Retirement not result of any disagreement with company operations or practices.SEC filing →
- 2026-05-29Item 5.02MEDIUMEva C. Boratto appointed EVP and CFO effective June 29, 2026, succeeding retiring CFO James F. Cleary. Cleary to serve in advisory capacity through end of 2026. Boratto most recently CFO of Bath & Body Works since August 2023.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $337.84: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Below-average business quality. Chart setup: RSI 58 mid-range, Bollinger mid-band. Prior stop was $323.96. Score 5.1/10, moderate confidence.
Analyst target $323.35 reached (−4.3% from $337.84); no take-profit level is published. Prior stop was $323.96. Stop-loss: $323.96.
Concentration risk — Customer: top ten customers (66.0%); Target reached (-4.3% upside); Quality below floor (3.9 < 4.0).
Cencora, Inc. trades at a P/E of 25.1 (forward 17.1). TrendMatrix value score: 6.5/10. Verdict: Sell.
20 analysts rate COR, with a consensus score of 3.9/5. 12 analysts publish price targets averaging $372.
What does Cencora, Inc. do?Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals,...
Cencora distributes brand-name, specialty, and generic pharmaceuticals and healthcare supplies to hospitals, pharmacies, physicians, and veterinarians across the U.S. and select global markets through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. Top-10 customers represented approximately 66% of fiscal 2025 revenue, with Walgreens and Boots at roughly 25% and Evernorth Health Services at roughly 13%.